Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients

Lupus

Volumn 23, Issue 3, 2014, Pages 245-254

  Parra, S ^a,c   Cabre A ^b   Marimon, F ^a   Ferre R ^a,b   Ribalta, J ^b   Gonzalez M ^b   Heras, M ^b   Castro, A ^a,c   Masana, L ^a,b  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c Sociedad Españ Ola de Medicina Interna SEMI   (Spain)

Author keywords

cardiovascular disease; changes; haematologic; Systemic lupus erythematosus

Indexed keywords

CARDIOVASCULAR DISEASE; CHANGES; HAEMATOLOGIC; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; LINEAR MODELS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE SPECTROSCOPY; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; RISK FACTORS; SPAIN;

EID: 84894033624     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313517405     Document Type: Article

References (42)

1. Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: Relation to disease activity and damage accrual. Lupus. 2007 ; 16: 309-317
2. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 ; 42: 338-346
3. Asanuma Yu, Oeser A, Ayumi K, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2407-2415
4. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008 ; 121: S3 - S8
5. Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007 ; 56: 3412-3419
6. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun Rev. 2008 ; 7: 246-250
7. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 ; 44: 2331-2337
8. Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus. 2008 ; 17: 849-859
9. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007 ; 66: 208-214
10. López-Pedrera C, Aguirre MÁ, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic lupus erythematosus: Role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol. 2010 ; 2010: 607084-607084
11. Goldberg RJ, Urowitz MB, Ibáñez D, Nikpour M, Gladman DD. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol. 2009 ; 36: 2454-2461
12. Parra S, Vives G, Ferré R, et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis. 2012 ; 225: 224-223
13. Vadacca M, Margiotta D, Rigon A, et al. Adipokines and systemic lupus erythematosus: Relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol. 2009 ; 36: 295-297
14. Telles RW, Lanna CCD, Ferreira GA, Ribeiro A. Metabolic syndrome in patients with systemic lupus erythematosus: Association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus. 2010 ; 19: 803-809
15. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, et al. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol. 2009 ; 36: 2204-2211
16. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med. 2004 ; 164: 1066-1076
17. Lozovoy MAB, Simão ANC, Hohmann MS, et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus. 2011 ; 20: 1356-1364
18. Chung CP, Long AG, Solus JF, et al. Adipocytokines in systemic lupus erythematosus: Relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009 ; 18: 799-806
19. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008 ; 134: 933-944
20. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and Ikappa B kinase activities. J Biol Chem. 2005 ; 280: 12888-12895
21. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006 ; 52: 405-413
22. Makowski L, Hotamisligil GS. The role of fatty acid-binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol. 2005 ; 16: 543-548
23. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmatic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009 ; 15: 1383-1391
24. Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001 ; 7: 699-705
25. Furuhashi M, Fucho R, Gorgun CZ, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008 ; 118: 2640-2650
26. Lázaro I, Díaz M, Cabré A, Masana L, Ibáñez L. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecol Endocrinol. 2011 ; 27: 935-939
27. Coll B, Cabre A, Alonso-Villaverde C, et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis. 2008 ; 199: 147-153
28. Bagheri R, Qasim A, Mehta NN, et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol. 2010 ; 106: 1118-1123
29. Holm S, Ueland T, Dahl TB, et al. Fatty acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PlosOne. 2011 ; 6: e28785 - e28785
30. Agardh HE, Folkersen L, Ekstrand J, et al. Expression of fatty-acid-binding protein aP2 is correlated with plaque instability in carotid atherosclerosis. J Intern Med. 2011 ; 269: 200-210
31. Cabré A, Lázaro I, Girona J, et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res. 2008 ; 4: 1746-1751
32. Cabré A, Lázaro I, Girona J, et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 2007 ; 195: e150 - e158
33. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1740
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-502
35. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
36. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005 ; 365: 1415-1428
37. Reilly MP, Wolfe ML, Rhodes T, et al. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004 ; 110: 803-809
38. Gonzàlez M, Ribalta J, Vives G, et al. Nuclear magnetic resonance lipoprotein subclasses and the APOE genotype influence carotid atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol. 2010 ; 37: 2259-2267
39. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008 ; 21: 93e111-93e111
40. Junyent M, Gilabert R, Núñez I, et al. Carotid ultrasound in the assessment of preclinical atherosclerosis. Distribution of intima-media thickness values and plaque frequency in a Spanish community cohort [article in Spanish]. Med Clin (Barc). 2005 ; 125: 770-774
41. Yeung DC, Xu A, Cheung CW, et al. Adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006 ; 27: 1796-1802
42. Aragonès G, Ferré R, Lázaro I, et al. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis. 2010 ; 213: 329-331